Ambeed.cn

首页 / 抑制剂/激动剂 / / FLT3 / Tandutinib

坦度替尼 /Tandutinib {[allProObj[0].p_purity_real_show]}

货号:A895261 同义名: 坦度替尼 (MLN518) / MLN518;CT53518 Ambeed 开学季,买赠积分,赢豪礼

Tandutinib is an antagonist of FLT3 with IC50 of 0.22 μM and can also inhibit PDGFR and c-Kit thereby inhibiting cellular proliferation and inducing apoptosis.

Tandutinib 化学结构 CAS号:387867-13-2
Tandutinib 化学结构
CAS号:387867-13-2
Tandutinib 3D分子结构
CAS号:387867-13-2
Tandutinib 化学结构 CAS号:387867-13-2
Tandutinib 3D分子结构 CAS号:387867-13-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Tandutinib 纯度/质量文件 产品仅供科研

货号:A895261 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JACS Au, 2024. Ambeed. [ A148168 ]
JMC, 2024. Ambeed. [ A187643 ]
JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
Biomacromolecules, 2024. Ambeed. [ A110759 ]
Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 FLT3 其他靶点 纯度
R406 Syk {[allProObj[0].p_purity_real_show]}
Go6976 {[allProObj[0].p_purity_real_show]}
Quizartinib +++

FLT3 (WT), IC50: 4.2 nM

FLT3 (ITD), IC50: 1.1 nM

{[allProObj[0].p_purity_real_show]}
Gilteritinib ++++

FLT3, IC50: 0.29 nM

{[allProObj[0].p_purity_real_show]}
Amuvatinib +

FLT3 (D835Y), IC50: 81 nM

{[allProObj[0].p_purity_real_show]}
Pacritinib ++

FLT3 (D835Y), IC50: 6 nM

FLT3, IC50: 22 nM

{[allProObj[0].p_purity_real_show]}
Dovitinib ++++

FLT3, IC50: 1 nM

c-Kit {[allProObj[0].p_purity_real_show]}
Denfivontinib ++++

FLT3 (D835Y), IC50: 0.4 nM

FLT3, IC50: 0.4 nM

RET {[allProObj[0].p_purity_real_show]}
TAK-659 HCl ++

FLT3, IC50: 4.6 nM

Syk {[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Tandutinib 生物活性

描述 Receptor tyrosine kinases (RTK) are mediators of cellular proliferation. These transmembrane RTKs contain an extracellular domain for ligand binding and intracellular kinase domains that mediate autophosphorylation, recruitment of downstream signaling molecules, and signal transduction. Type III RTKs, such as PDGFR (platelet-derived growth factor receptor), FGFR (fibroblast growth factor receptor), VEGFR (vascular endothelial growth factor receptor), FLT3 and c-KIT are often overexpressed in tumor and implicated in tumor growth and progression. Tandutinib is an inhibitor of FLT3, PDGFR and c-Kit. The kinase inhibitory IC50s were 0.22, 0.20 and 0.17 μM, respectively. Tandutinib inhibited phosphorylation of WT FLT3 and FLT3-ITD (internal tandem duplication) in Ba/F3 cells with IC50s of 30-100nM. Tandutinib inhibited cell proliferation of the FLT3-ITD-positive cells (Molm-13 and Molm-14 cells) with an IC50 value of 10 nM, whereas the FLT3-ITD-negative cells (THP-1, KG-1, and RS4 cells) were resistant, requiring 1000-fold higher concentrations to inhibit cell growth. Treatment of Molm-14 cells with 1 μM tandutinib resulted in an increase of the percentage of apoptotic cells from a background level of 5% to 51% at 24h and 78% at 96h. Tandutinib preferentially inhibited the growth of blast colonies derived from FLT3 ITD-positive patients with IC50s between 75 and 400 nM. In a nude mice model established by injection of FLT3-ITD-transformed Ba/F3 cells, oral administration of tandutinib at 60 mg/kg bid significantly increased the survival of mice and resulted in a significant reduction in mortality in a mouse bone marrow transplantation model.
作用机制 Tandutinib inhibits FLT3, PDGFR and c-Kit in an ATP competitive manner.

Tandutinib 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00064584 Acute Myelogenous Leukemia ... 展开 >> Myelodysplastic Syndrome 收起 << Phase 1 Completed - United States, California ... 展开 >> UCLA Medical Center Los Angeles, California, United States, 90095 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10021 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Oregon Oregon Health Sciences University Portland, Oregon, United States, 97201 收起 <<
NCT00274248 Acute Myelogenous Leukemia Phase 1 Completed - United States, Massachusetts ... 展开 >> The Dana Farber Cancer Institute Boston, Massachusetts, United States, 02134 收起 <<
NCT00297921 Acute Myelogenous Leukemia Phase 1 Phase 2 Withdrawn - -

Tandutinib 参考文献

[1]Griswold IJ, Shen LJ, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 2004 Nov 1;104(9):2912-8.

[2]Kelly LM, Yu JC, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002 Jun;1(5):421-32.

Tandutinib 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.89mL

1.78mL

0.89mL

17.77mL

3.55mL

1.78mL

Tandutinib 技术信息

CAS号387867-13-2
分子式C31H42N6O4
分子量 562.703
别名 坦度替尼 (MLN518) ;MLN518;CT53518;MLN0518, MLN 518, MLN-518, MLN518, NSC726292, NSC 726292, NSC-726292, CT53518, CT-53518, CT 53518, D06005, D-06005, D 06005, Tandutinib;NSC726292
运输蓝冰
存储条件

粉末 Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 50 mg/mL(88.86 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

0.5% methylcellulose+water 30 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。